(firstQuint)Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults.

 This is a double-blind and randomized study in healthy adults.

 The duration of study will be approximately 90 days per participant.

 The study will include 4 visits: Day 1 (for vaccination), Day 4, Day 22 and day 90 (Follow-up visits).

 Safety and tolerability will be assessed by the rate of solicited, unsolicited, and serious adverse events.

.

 Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults@highlight

The purpose of this study is to examine the safety and tolerability after administration of trivalent and quadrivalent cell-based virosomal influenza vaccine in healthy adults.

